HC Wainwright & Co. Reiterates Buy on Macrogenics, Maintains $14 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Robert Burns has reiterated a 'Buy' rating on Macrogenics (NASDAQ:MGNX) and maintained a $14 price target.
August 10, 2023 | 11:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated a 'Buy' rating on Macrogenics and maintained a $14 price target.
The reiteration of a 'Buy' rating and maintenance of a $14 price target by HC Wainwright & Co. indicates a positive outlook for Macrogenics. This could potentially lead to an increase in investor confidence and a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100